DR Congo’s Bundibugyo Ebola Outbreak: A Rapidly Expanding Crisis DATELINE: Kampala, Uganda – LEDE: The Democratic Republic of the Congo (DRC) is facing one of its most severe Ebola outbreaks, with the Bundibugyo virus claiming numerous lives and spreading across multiple provinces. NUT GRAF: As of 19 July 2026, the DRC has reported 2,423 confirmed cases of Ebola, including 967 deaths and 469 recoveries.
The outbreak, centered in Ituri province, has been challenging due to remote and densely populated areas, insecurity, and high population and trade movements.
Kampala, Uganda — The Democratic Republic of the Congo (DRC) is addressing a rapidly expanding Ebola outbreak caused by the Bundibugyo virus, with the situation growing increasingly dire as the virus spreads across multiple provinces.
As of 19 July 2026, the DRC has reported a cumulative of 2,423 confirmed cases, including 967 deaths and 469 recoveries.
The epicenter of the outbreak remains Ituri province, accounting for over 90% of cases and 80% of deaths.
The Bundibugyo virus is one of the five Ebola virus species known to infect humans, and this outbreak marks the first time it has caused such a significant public health emergency. Unlike the more common Zaire strain, there is currently no vaccine or specific treatment for Bundibugyo Ebola. Research is ongoing, with the World Health Organization (WHO) recommending prioritizing several experimental drugs, including antibodies, antivirals, and vaccines, for the treatment and prevention of the disease.
The WHO and national authorities in the DRC and Uganda are collaborating on an extensive set of response measures, including surveillance, contact tracing, clinical preparedness, and community engagement.
The Centers for Disease Control and Prevention (CDC) has indicated that the risk to the American public and travelers from this outbreak remains low.
The outbreak has been challenging to contain due to the remote and densely populated areas affected, as well as ongoing insecurity.
The PARTNERS clinical trial, sponsored by the WHO, has opened enrollment for patients in the DRC to evaluate potential treatments for Bundibugyo virus disease.
The trial will assess whether two antiviral therapies — a monoclonal antibody (MBP134) and remdesivir – can improve survival among people diagnosed with the disease.
As the outbreak continues to expand, the DRC government and its partners are working tirelessly to contain the virus and prevent further transmission.
The situation remains critical, and the global community is closely monitoring the developments in the DRC. KICKER: The rapid expansion of the Bundibugyo Ebola outbreak in the DRC underscores the need for a coordinated and comprehensive response to contain the virus and protect vulnerable populations.
The ongoing research and international collaboration are crucial in finding effective treatments and preventing further spread of the disease.
*Additional reporting by ImNews | Sources consulted: 5*
—
This original article was produced by the ImNews editorial team
Source: reliefweb
Source: International Organization for Migration
